# Cannabidiol: Attenuation of Behavioral and Cognitive Schizophrenia Symptoms Leads to Potential Clinical Applications > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabidiol-antipsychotic-effects-schizophrenia-research/ > **Published:** 2021-03-09T14:22:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:12-04:00 > **Clinical Summary:** Explore cannabidiol antipsychotic effects schizophrenia research showing CBD's potential in treating behavioral and cognitive symptoms via 5-HT1A receptor. --- ### Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors In Summary Although cannabidiol (CBD), a major constituent of the plant cannabis, is known to have antipsychotic effects, its effects on the negative and cognitive symptoms of schizophrenia are currently not well understood. Hence, a study was recently conducted on mice models of this disease to evaluate whether CBD could reduce the negative behavioral and cognitive deficits and additionally, identify the molecular target of these therapeutic actions. By treating male mice with a chemical blocker of the NMDA brain receptor for 14 days, researchers created mice with deficits in the social interaction (SI) and novel object recognition (NOR) tests, which have been used to investigate the negative and cognitive symptoms of schizophrenia, respectively. These mice then received CBD injection for 7 days, after which they were re-assessed using the same tests. Data showed that CBD delivers similar therapeutic results as a drug currently used to treat schizophrenia. In follow-up experiments, after blockage of NMDA, the researchers also used chemical compounds to inhibit the [cannabinoid receptor type 1](https://cedclinic.com/mediation-of-the-cannabinoid-receptor-type-1-can-enhance-the-antidepressant-powers-of-conventional-therapy/) (CB1), cannabinoid receptor type 2 (CB2), or the serotonin 1A receptor (5-HT1A) in different groups of mice. These three groups of mice then also received CBD injection and re-assessment. Data suggested that the therapeutic effects of CBD were lost in the mice treated with 5-HT1A inhibitor, but not in the other groups. This was intriguing, since the [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) have been known to interact with components of cannabis – hence their names – including CBD. In summary, the study proved that CBD attenuates behavioral and cognitive impairments in the mice model of schizophrenia by activation of 5-HT1A receptor and therefore serve as a potential treatment of many severe symptoms of this mental illness. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid receptor type 2 as a promising new target for schizophrenia drugs](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/) Explore the role of cannabinoid receptor type 2 in schizophrenia [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) and its therapeutic potential. [Read More](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/) [Distinct Effects of 9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing](https://cedclinic.com/distinct-effects-tetrahydrocannabinol-cannabidiol-neural-activation/) Understand how THC and CBD differently affect brain activity related to emotional processing. [Discover Insights](https://cedclinic.com/distinct-effects-tetrahydrocannabinol-cannabidiol-neural-activation/) [Study Challenges Negative Cannabis Stereotypes, Claiming Link to Brain Benefits](https://cedclinic.com/cannabis-brain-volume-study-cognitive-benefits/) This study provides evidence challenging negative views on cannabis, highlighting potential [brain health](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) benefits. [Learn More](https://cedclinic.com/cannabis-brain-volume-study-cognitive-benefits/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabidiol%3A%20Attenuation%20of%20Behavioral%20and%20Cognitive%20Schizophrenia%20Symptoms%20Leads%20to%20Potential%20Clinical%20Applications&url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-antipsychotic-effects-schizophrenia-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-antipsychotic-effects-schizophrenia-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabidiol%3A%20Attenuation%20of%20Behavioral%20and%20Cognitive%20Schizophrenia%20Symptoms%20Leads%20to%20Potential%20Clinical%20Applications%20https%3A%2F%2Fcedclinic.com%2Fcannabidiol-antipsychotic-effects-schizophrenia-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).